Cannabinoids in Bipolar Affective Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00397605|
Recruitment Status : Withdrawn (study was never started and no patients were ever enrolled)
First Posted : November 9, 2006
Last Update Posted : September 18, 2014
|Condition or disease||Intervention/treatment||Phase|
|Bipolar Affective Disorder||Drug: Synthetic cannabinoids (1:1 ratio of THC % CBD)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Cannabinoids in Bipolar Affective Disorder: A Controlled Pilot Study|
|Study Start Date :||November 2006|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||December 2013|
Drug: Synthetic cannabinoids (1:1 ratio of THC % CBD)
Randomized crossover study of 2 weeks of active study medication (maximum daily dosage of 60 mg) vs. 2 weeks of matching placebo.
- To determine whether a standardized plant extract of cannabis containing a 1:1 ratio of THC & CBD can alleviate bipolar mood symptoms unresponsive to standard treatment. To be measured weekly over 13 weeks. [ Time Frame: 13 weeks ]
- To determine the effects on cognition.
- To be measured at baseline and at the end of each treatment phase.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00397605
|Canada, British Columbia|
|Department of Psychiatry, University of British Columbia|
|Vancouver, British Columbia, Canada, V6T 2A1|
|Principal Investigator:||Allan H. Young, Ph.D||University of British Columbia|